|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | No. of studies | No. of experimental group | No. of control group | RR | 95% CI | *p* | Heterogeneity |
| (I2) (%) |
| Alopecia | 3 | 1454 | 928 | 0.82 | 0.26-2.56 | 0.73 | 0 |
| ALT increased | 5 | 1810 | 1255 | 1.58 | 0.96-2.61 | 0.07 | 0 |
| Anemia | 5 | 1810 | 1255 | 0.99 | 0.68-1.43 | 0.95 | 19 |
| Decreased appetite | 5 | 1280 | 1021 | 1.11 | 0.38-3.25 | 0.85 | 0 |
| Diarrhoea | 5 | 1280 | 1021 | 0.65 | 0.34-1.24 | 0.19 | 0 |
| Dyspnea | 5 | 1280 | 1021 | 1.44 | 0.53-3.93 | 0.47 | 0 |
| Fatigue | 5 | 1810 | 1255 | 1.05 | 0.66-1.67 | 0.85 | 0 |
| Hypothyroidism | 3 | 918 | 608 | 3.00 | 0.51-17.68 | 0.23 | 0 |
| Nausea | 5 | 1795 | 1267 | 0.80 | 0.39-1.67 | 0.56 | 0 |
| Neutropenia | 5 | 1410 | 1085 | 0.59 | 0.23-1.51 | 0.27 | 83 |
| Pneumonia | 5 | 1795 | 1267 | 3.74 | 1.45-9.65 | *0.006* | 0 |
| Pyrexia | 5 | 1280 | 1021 | 1.09 | 0.43-2.76 | 0.86 | 0 |

**Supplementary Table 4.** Subgroup analysis of the AEs (grade more than 3) of of unresectable locally advanced or metastatic triple negative breast cancer (TNBC) with programmed cell death protein 1/programmed apoptosis ligand 1 (PD-1/PD-L1) inhibitor based immunotherapy combined with chemotherapy, versus other treatments

PD-1/PD-L1: PD-1/PD-L1: programmed cell death protein 1/programmed cell death 1 ligand 1; AEs: adverse events; RR: risk ratio; Cl: confidence interval; ALT: alanine aminotransferase